BIOMAT Database Logo BIOMAT Database Logo

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. 1996

J C Schmit, and J Cogniaux, and P Hermans, and C Van Vaeck, and S Sprecher, and B Van Remoortel, and M Witvrouw, and J Balzarini, and J Desmyter, and E De Clercq, and A M Vandamme
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.

A human immunodeficiency virus type 1 (HIV-1)-seropositive patient was treated sequentially with the dideoxynucleoside (ddN) analogues zidovudine, didanosine, zalcitabine, stavudine, and lamivudine and the nonnucleoside HIV-1-specific reverse transcriptase inhibitor (NNRTI) loviride (alpha-APA). Accumulation of drug resistance mutations (mainly V75I, F77L, K103N, F116Y, Q151M, and M184V) eventually resulted in a strain that was genotypically and phenotypically resistant to all tested ddNs and the majority of NNRTIs. However, the multidrug-resistant virus retained wild type sensitivities to drugs such as foscarnet, phosphonomethoxyethyl adenine, dextran sulfate, JM3100, saquinavir, and NNRTI TSAO-m3T. Drug-resistant isolates showed replication kinetics and infectivity in an in vitro peripheral blood mononuclear cell system similar to those of the wild type isolate from the same patient. The multi-ddN-resistant isolate was not eliminated in a competition culture with the wild type isolate. Sequential therapy did not prevent the appearance of multidrug-resistant virus with a conserved replication rate.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse

Related Publications

J C Schmit, and J Cogniaux, and P Hermans, and C Van Vaeck, and S Sprecher, and B Van Remoortel, and M Witvrouw, and J Balzarini, and J Desmyter, and E De Clercq, and A M Vandamme
Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
August 2006, Antimicrobial agents and chemotherapy,
J C Schmit, and J Cogniaux, and P Hermans, and C Van Vaeck, and S Sprecher, and B Van Remoortel, and M Witvrouw, and J Balzarini, and J Desmyter, and E De Clercq, and A M Vandamme
Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1.
March 1995, The Journal of infectious diseases,
J C Schmit, and J Cogniaux, and P Hermans, and C Van Vaeck, and S Sprecher, and B Van Remoortel, and M Witvrouw, and J Balzarini, and J Desmyter, and E De Clercq, and A M Vandamme
Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
September 2005, Journal of virology,
J C Schmit, and J Cogniaux, and P Hermans, and C Van Vaeck, and S Sprecher, and B Van Remoortel, and M Witvrouw, and J Balzarini, and J Desmyter, and E De Clercq, and A M Vandamme
Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
January 2004, Current topics in medicinal chemistry,
J C Schmit, and J Cogniaux, and P Hermans, and C Van Vaeck, and S Sprecher, and B Van Remoortel, and M Witvrouw, and J Balzarini, and J Desmyter, and E De Clercq, and A M Vandamme
The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.
January 2006, Antimicrobial agents and chemotherapy,
J C Schmit, and J Cogniaux, and P Hermans, and C Van Vaeck, and S Sprecher, and B Van Remoortel, and M Witvrouw, and J Balzarini, and J Desmyter, and E De Clercq, and A M Vandamme
Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
April 2008, Journal of virology,
J C Schmit, and J Cogniaux, and P Hermans, and C Van Vaeck, and S Sprecher, and B Van Remoortel, and M Witvrouw, and J Balzarini, and J Desmyter, and E De Clercq, and A M Vandamme
The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.
April 2009, Journal of virology,
J C Schmit, and J Cogniaux, and P Hermans, and C Van Vaeck, and S Sprecher, and B Van Remoortel, and M Witvrouw, and J Balzarini, and J Desmyter, and E De Clercq, and A M Vandamme
Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.
September 1994, Antimicrobial agents and chemotherapy,
J C Schmit, and J Cogniaux, and P Hermans, and C Van Vaeck, and S Sprecher, and B Van Remoortel, and M Witvrouw, and J Balzarini, and J Desmyter, and E De Clercq, and A M Vandamme
Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.
April 2011, Antimicrobial agents and chemotherapy,
J C Schmit, and J Cogniaux, and P Hermans, and C Van Vaeck, and S Sprecher, and B Van Remoortel, and M Witvrouw, and J Balzarini, and J Desmyter, and E De Clercq, and A M Vandamme
Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.
October 2001, Journal of virology,
Copied contents to your clipboard!